SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Syneos Health, Inc. (SYNH) trades at a trailing P/E of 16.9. Trailing earnings yield is 5.91%. PEG 1.26.
Criteria proven by this page:
- VALUE (93/100, Pass) — P/E is below market average (16.9); analyst target implies upside (+67.5%); earnings yield beats bond yields (5.91%).
- PEG Ratio 1.26 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 5.91% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
- Analyst consensus target $72.00 (+67.5% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 67/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
93/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SYNH
Valuation Multiples
P/E (TTM)16.9
Forward P/EN/A
PEG Ratio1.26
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.82
EV/EBITDA0.0
Per Share Data
EPS (TTM)$2.54
Book Value / Share$0.00
Revenue / Share$52.12
FCF / Share$0.00
Yields & Fair Value
Earnings Yield5.91%
Dividend Yield0.00%
Analyst Target$72.00 (+67.5%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-0.80 |
$995.09M |
$-41.53M |
-4.2% |
| 2014 |
$-0.44 |
$1.18B |
$-23.47M |
-2% |
| 2015 |
$1.95 |
$1.4B |
$117.05M |
8.4% |
| 2016 |
$2.03 |
$1.61B |
$112.63M |
7% |
| 2017 |
$-1.85 |
$2.67B |
$-138.47M |
-5.2% |
| 2018 |
$0.23 |
$4.39B |
$24.28M |
0.6% |
| 2019 |
$1.25 |
$4.68B |
$131.26M |
2.8% |
| 2020 |
$1.83 |
$4.42B |
$192.79M |
4.4% |
| 2021 |
$2.24 |
$5.21B |
$234.83M |
4.5% |
| 2022 |
$2.54 |
$5.39B |
$266.5M |
4.9% |
